Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72597
Title:
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Authors:
Shanley, Susan; McReynolds, Kate; Ardern-Jones, Audrey; Ahern, Roger; Fernando, Indrajit; Yarnold, John; Evans, D Gareth R; Eccles, Diana; Hodgson, Shirley V; Ashley, Sue; Ashcroft, Linda; Tutt, Andrew; Bancroft, Elizabeth; Short, Susan; Smith, Ian; Gui, Gerald; Barr, Lester; Baildam, Andrew D; Howell, Anthony ( 0000-0002-3879-5991 ) ; Royle, Gavin; Pierce, Lori; Easton, Douglas; Eeles, Rosalind
Abstract:
PURPOSE: To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003. EXPERIMENTAL DESIGN: All participants were interviewed by one of two researchers using standardized questionnaires, and their medical records were reviewed by one research nurse. The two main regimens received were cyclophosphamide, methotrexate, and fluorouracil and fluorouracil, epirubicin, and cyclophosphamide. The proportion of cases and controls receiving anthracycline-based treatment was equivalent, but fewer BRCA1 cases received this treatment than did BRCA2 mutation carriers. Toxicity was documented using the Eastern Cooperative Oncology Group Common Toxicity Criteria for hematologic, infective, and gastrointestinal toxicities. No increase in toxicity was seen in BRCA1/2 mutation carriers. RESULTS: The only significant difference was that neutropenia was less evident in BRCA2 mutation carriers than in either BRCA1 mutation carriers or controls. As a result, there was no requirement for dose reduction among BRCA2 mutation carriers, in contrast to 10 of 39 BRCA1 carriers and 16 of 62 controls (P = 0.02). CONCLUSIONS: This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers.
Affiliation:
Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. shanleysusan@hotmail.com
Citation:
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. 2006, 12 (23):7033-8 Clin. Cancer Res.
Journal:
Clinical Cancer Research
Issue Date:
1-Dec-2006
URI:
http://hdl.handle.net/10541/72597
DOI:
10.1158/1078-0432.CCR-06-1246
PubMed ID:
17145825
Type:
Article
Language:
en
ISSN:
1078-0432
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorShanley, Susan-
dc.contributor.authorMcReynolds, Kate-
dc.contributor.authorArdern-Jones, Audrey-
dc.contributor.authorAhern, Roger-
dc.contributor.authorFernando, Indrajit-
dc.contributor.authorYarnold, John-
dc.contributor.authorEvans, D Gareth R-
dc.contributor.authorEccles, Diana-
dc.contributor.authorHodgson, Shirley V-
dc.contributor.authorAshley, Sue-
dc.contributor.authorAshcroft, Linda-
dc.contributor.authorTutt, Andrew-
dc.contributor.authorBancroft, Elizabeth-
dc.contributor.authorShort, Susan-
dc.contributor.authorSmith, Ian-
dc.contributor.authorGui, Gerald-
dc.contributor.authorBarr, Lester-
dc.contributor.authorBaildam, Andrew D-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorRoyle, Gavin-
dc.contributor.authorPierce, Lori-
dc.contributor.authorEaston, Douglas-
dc.contributor.authorEeles, Rosalind-
dc.date.accessioned2009-07-06T14:02:43Z-
dc.date.available2009-07-06T14:02:43Z-
dc.date.issued2006-12-01-
dc.identifier.citationAcute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. 2006, 12 (23):7033-8 Clin. Cancer Res.en
dc.identifier.issn1078-0432-
dc.identifier.pmid17145825-
dc.identifier.doi10.1158/1078-0432.CCR-06-1246-
dc.identifier.urihttp://hdl.handle.net/10541/72597-
dc.description.abstractPURPOSE: To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003. EXPERIMENTAL DESIGN: All participants were interviewed by one of two researchers using standardized questionnaires, and their medical records were reviewed by one research nurse. The two main regimens received were cyclophosphamide, methotrexate, and fluorouracil and fluorouracil, epirubicin, and cyclophosphamide. The proportion of cases and controls receiving anthracycline-based treatment was equivalent, but fewer BRCA1 cases received this treatment than did BRCA2 mutation carriers. Toxicity was documented using the Eastern Cooperative Oncology Group Common Toxicity Criteria for hematologic, infective, and gastrointestinal toxicities. No increase in toxicity was seen in BRCA1/2 mutation carriers. RESULTS: The only significant difference was that neutropenia was less evident in BRCA2 mutation carriers than in either BRCA1 mutation carriers or controls. As a result, there was no requirement for dose reduction among BRCA2 mutation carriers, in contrast to 10 of 39 BRCA1 carriers and 16 of 62 controls (P = 0.02). CONCLUSIONS: This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCase-Control Studies-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshGenes, BRCA1-
dc.subject.meshGenes, BRCA2-
dc.subject.meshGerm-Line Mutation-
dc.subject.meshGreat Britain-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshRadiotherapy-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Outcome-
dc.titleAcute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.en
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. shanleysusan@hotmail.comen
dc.identifier.journalClinical Cancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.